
|Videos|February 27, 2017
Medicare Part D and Oncology
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.
Advertisement
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First-in-Class Daraxonrasib for Metastatic Pancreatic Cancer
2
What Pharmacists Should Know About Novo Nordisk-Eli Lilly GLP-1 Ad Suit
3
FDA Approves Dolutegravirfor HIV Treatment in Newborns
4
FDA Clears First Continuous Glucose-Ketone Monitor
5

































































































